The magnitude of OS benefit with upfront HDT is cytogenetics-dependent. Patients with high-risk cytogenetics should preferably receive upfront rather...
I risultati suggeriscono la potenziale utilità dell’analisi del cfDNA nel plasma del sangue periferico dei pazienti come biomarcatore rilevante per l...
This makes an interdisciplinary approach mandatory for the management of these patients, to provide the best care possible based on tumor size, site...